Following CAR-T safety label changes, FDA officials share new details about secondary cancer cases

More than half of the cancer cases the FDA is examining as part of its CAR-T safety investigation occurred within two years of treatment, according to an editorial penned by top FDA officials and published Wednesday.

Nicole Verdun

The FDA is investigating 22 cases of…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks